McClung, M R, Bolognese, M A, Brown, J P, Reginster, J Y, Langdahl, B L, Maddox, J, Shi, Y, Rojeski, M, Meisner, P D & Grauer, A 2020, ' A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab ', Osteoporosis International, vol. 31, no. 11, pp. 2231-2241 . https://doi.org/10.1007/s00198-020-05502-0 Osteoporosis International
McClung, M R, Bolognese, M A, Brown, J P, Reginster, J Y, Langdahl, B L, Shi, Y, Timoshanko, J, Libanati, C, Chines, A & Oates, M K 2021, ' Skeletal responses to romosozumab after 12 months of denosumab ', JBMR Plus, vol. 5, no. 7, e10512 . https://doi.org/10.1002/jbm4.10512 JBMR Plus, Vol 5, Iss 7, Pp n/a-n/a (2021) JBMR Plus
Langdahl, B L, Libanati, C, Crittenden, D B, Bolognese, M A, Brown, J P, Daizadeh, N S, Dokoupilova, E, Engelke, K, Finkelstein, J S, Genant, H K, Goemaere, S, Hyldstrup, L, Jodar-Gimeno, E, Keaveny, T M, Kendler, D, Lakatos, P, Maddox, J, Malouf, J, Massari, F E, Molina, J F, Ulla, M R & Grauer, A 2017, ' Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy : a randomised, open-label, phase 3 trial ', Lancet, vol. 390, no. 10102, pp. 1585-1594 . https://doi.org/10.1016/S0140-6736(17)31613-6